UBC® Rapid
Rapid urine test for bladder cancer detection and monitoring
UBC® Rapid is a non-invasive urine-based test for bladder cancer detection and monitoring. Designed for point-of-care use, it provides rapid results to support clinical decision-making in patients with suspected or confirmed bladder cancer, including non-muscle invasive bladder cancer (NMIBC).
What is UBC® Rapid?
The test measures soluble fragments of cytokeratin 8 and 18, proteins released from urothelial tumor cells and detectable in urine samples. These biomarkers are associated with tumor activity and may provide valuable diagnostic information.
The test enables fast, non-invasive assessment of bladder cancer status and can be performed directly at the point of care.
What are the key benefits of UBC® Rapid for bladder cancer detection?
- Non-invasive bladder cancer test using urine samples
- Rapid results at the point of care, enabling same-visit clinical insight
- Supports early detection of tumor activity and recurrence
- Complements cystoscopy and urine cytology in clinical practice
- Designed for easy integration into routine workflows
Clinical value in non-muscle invasive bladder cancer
UBC® Rapid supports multiple clinical use cases:
- Detection of bladder cancer
- Monitoring of non-muscle invasive bladder cancer (NMIBC)
- Identification of tumor activity and recurrence
- Supporting follow-up strategies in urology
Intended use
UBC® Rapid is intended to be used as an aid in the detection and monitoring of bladder cancer, in conjunction with established diagnostic procedures.
IDL Biotech is the legal manufacturer of UBC® Rapid.
How does UBC® Rapid supports clinical workflows?
- Enables rapid screening during patient visits
- Provides additional data alongside cytology and imaging
- Can be used to support ongoing monitoring strategies
- Reduces reliance on invasive procedures for routine assessment
Why choose UBC® Rapid for bladder cancer management?
Early detection and efficient monitoring are critical in bladder cancer management. UBC® Rapid combines speed, simplicity, and clinically relevant biomarker detection to support informed decision-making in routine practice.
Cytokeratin
Most eukaryotic cells have cytoplasmic cytoskeletal structures known as intermediate filaments. The cytoskeletal network is responsible for the mechanical integrity of the cell, and it is critical during cellular processes like cell division, motility and cell to cell contacts. At present more than 20 different cytokeratins have been identified, of which cytokeratin 8, 18, and 19 are the most abundant in simple epithelial cells. The cytokeratins are epithelial cell-specific and the cytokeratin pattern is usually preserved during the transformation of normal cells into malignant cells.
Cytokeratins in cancer
Cancer affects everyone – the young and old, the rich and poor, men, women, and children – and represents a tremendous burden on patients, families, and societies. Cancer is one of the leading causes of death in the world.
Normal cells are constantly dividing, but in cancer, abnormal cell growth occurs. This causes the protein cytokeratin to leak out which can be measured with efficient diagnostic tools. Thanks to modern technology, AroCell can quickly diagnose several kinds of cancer non-invasive and pain-freely.
Find more information
UBC® Rapid is a powerful diagnostic parameter in aid of diagnosis and follow-up of bladder cancer, especially for papillary non-invasive high-grade tumors and carcinoma in situ (CIS).
Clinical evaluation
UBC® Rapid performs better than urine cytology in many patients due to improved sensitivity and the combination of UBC® Rapid and cytology enables detection of additional tumors as opposed to cytology alone.
References for UBC® Rapid
1. Giannopoulus A., et al. Comparative evaluation of the diagnostic performance of the BTA Stat test,NMP22 and Urinary Bladder Cancer antigen for primary and recurrent bladder tumors. J Urol 2001; 166:470-475.
2. Lüdecke G., et al. Comparative analysis of sensitivity to blood in the urine for urine-based point-of-care assays (UBC® Rapid, NMP22 BladderChek and BTA-stat) in primary diagnosis of bladder carcinoma. Interference of blood on the result of urine-based POC tests. Anticancer Res 2012; 32:2015-2018.
3. Ritter R., et al. Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer. Urol Oncol 2014; 32:337-344.
4. Ecke T., et al. Preliminary results of a multicentre-study of the UBC® Rapid for detection of urinary bladder cancer. Anticancer Res 2015; 35:2651-2656.
5. Styrke J., et al. Evaluation of the diagnostic accuracy of UBC® Rapid in bladder cancer: a Swedish multicentre study. Scand J Urol 2017; 51:293-300.
6. Ecke T., et al. UBC® Rapid Test for detection of carcinoma in situ (CIS) in urinary bladder cancer. Tumor Biol 2017; 39:1-7.
7. Pichler R., et al. Urinary Rapid and NMP22 test for bladder cancer surveillance in comparison to urinary cytology: Results from a prospective single-center study. Int J Med Sci 2017; 14:811-819.
8. Gleichenhagen J., et al. Evaluation of a new Survivin ELISA and UBC® Rapid for the detection of bladder cancer in urine. Int J Mol Sci 2018; 19:226-239
Oncology
Diagnostics for oncology
Cancer is one of the leading causes of death worldwide, despite advancing knowledge. To improve cancer patient management, there is a clear need for efficient diagnostics tools to capture this critical clinical data.
Bacteriology
An effective typhoid test
Typhoid fever is water and food-borne infectious disease caused by the bacterium, Salmonella enterica. IDL Biotechs product TUBEX® TF, is a rapid and sensitive in vitro diagnostic test for the detection of acute typhoid fever.
Investors
We are listed on NASDAQ First North Growth Market.
We want to be the obvious choice within our segment in the markets where we are established. The market for our products is large and we are a smaller player with significant growth potential so far. IDL Diagnostics is unique for a company of this size.
